Key result
Elevated anti-skeletal muscle glycolipid antibodies predict grade 2+ histological rejection and future rejection episodes.
Why the study?
Does the serum titer of anti-skeletal muscle glycolipid antibodies correlate with histological acute rejection in heart transplant patients?
Observational (n=17)
Does the serum titer of anti-skeletal muscle glycolipid antibodies correlate with histological acute rejection in heart transplant patients?
p-value: p=<0.005
Serum anti-skeletal muscle glycolipid antibodies may serve as a useful noninvasive biomarker for monitoring acute cellular rejection following heart transplantation.
No takes yet. Share an insight, caveat, or question.
May support noninvasive rejection monitoring after heart transplant; leaves open prospective validation before clinical adoption.
Laguens et al. (1996) conducted an observational in Heart transplantation (n=17). Anti-skeletal muscle glycolipid antibodies (AGA) vs. Low AGA titer / less severe rejection grades was evaluated on Histological rejection grades with myocyte necrosis (≥2) (p=<0.005). Elevated anti-skeletal muscle glycolipid antibody titers were significantly associated with histological rejection grades ≥2 (P<0.005) and predicted future rejection episodes (P<0.05).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: